MedTrace Logo

QA108 Phase III Study in Subjects With Intermediate AMD

NCT07189169 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-09-23

No results posted yet for this study

Summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Conditions

  • Intermediate Age-Related Macular Degeneration

Interventions

DRUG

QA108 granules

Take the medication as required for 24 weeks

DRUG

QA108 granules placebo

Take the medication as required for 24 weeks

Sponsors & Collaborators

  • Smilebiotek Zhuhai Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-08
Primary Completion
2027-03-01
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07189169 on ClinicalTrials.gov